140+ Pre-clinical & clinical studies on NR in various stages of completion representing $50 million of non-paid research.

NIAGEN® is the only proprietary nicotinamide riboside approved as a New Dietary Ingredient and that has achieved GRAS status.

Scientists now understand that low NAD or relative NAD-deficiency may be associated with many health-related problems of aging (e.g. Alzheimer's, hypertension, obesity, diabetes, etc.)

NIAGEN raises NAD levels in humans.

NIAGEN has reached the significant milestone of 18 human clinical trials in various stages of completion, with 11 of these trials looking at specific efficacy endpoints.

14 licensed global patents or patents pending.

Links to ongoing studies and publications: